Anavex Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, announced that 92 patients with Rett syndrome have been enrolled in the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 study in Rett syndrome patients aged 5 years (inclusive). This exceeds the original enrollment goal.

Publish Date: 02-02-2023 Source: Anavex Life Sciences Corp.

Rett syndrome (RTT) is a rare genetic neurological disorder that primarily affects girls and causes severe impairments in nearly every aspect of the child’s life, including their ability to speak, walk, eat, and even breathe easily. Rett syndrome is usually recognized in children aged 6 to 18 months when they begin to miss developmental milestones or lose previously acquired abilities. RTT is caused by mutations on the X chromosome on a gene called MECP2. The early-onset seizure type (Hanefeld variant) is frequently caused by mutations in the X-linked CDKL5 gene (Xp22). A translocation involving the NTNG1 gene (1p13.2-p13.1) has also been identified in a patient with early seizures and atypical RTT. The congenital variant (Rolando variant) is generally caused by mutations in the FOXG1 gene (14q11-q13).

The prevalence of Rett syndrome varies worldwide; in the USA, the estimated prevalence is 0.45 to 0.76 cases per 10,000 females aged 2 to 18 years. Germany is the leading and followed by France in the EU region in terms of total diagnosed and prevalent cases.

However, the current Rett Syndrome treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Trofinetide, VYNT-0126, EPI-743, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Rett Syndrome treatment. The key companies in the advanced development stage are ACADIA Pharmaceuticals Inc., Vyant Bio, Edison Pharmaceuticals Inc, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Rett Syndrome to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.